Vertex Pharmaceuticals’ Symkevi (tezacaftor/ivacaftor) is one step closer to being approved in the European Union as a treatment for cystic fibrosis (CF) patients ages 12 or older who have certain CFTR genetic mutations. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of the combo therapy […]
The post European Committee Recommends Approval of Vertex’s Combo Therapy Symkevi for Certain CF Patients appeared first on Cystic Fibrosis News Today. |
No hay comentarios:
Publicar un comentario